Cure My Disease

Don't miss your cure!

 Log in / Sign up

New asthma inhaler trial for kids: could improve breathing

NCT ID NCT05222529

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 16, 2026 · Updated 3 times

Summary

This study tests two doses of an inhaled drug called glycopyrronium in 42 children aged 6 to 12 with moderate to severe asthma. The goal is to see how well it opens airways and how safe it is compared to a placebo. Results will help decide the best dose for future combination treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Glycopyrronium bromide (an inhaled bronchodilator)
What this could lead to
If successful, this could help determine the right dose of glycopyrronium for children with asthma, potentially leading to a new combination inhaler that improves breathing control.
What could go wrong
This is an early Phase 2 trial with only 42 children, so results may not apply to all. The drug is already used in adults, but its effectiveness and safety in children are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Locations

  • Novartis Investigative Site

    RECRUITING

    Rousse, 7002, Bulgaria

  • Novartis Investigative Site

    RECRUITING

    Sevlievo, 5400, Bulgaria

  • Novartis Investigative Site

    RECRUITING

    Sofia, 1510, Bulgaria

  • Novartis Investigative Site

    RECRUITING

    Ibague, Tolima Department, 730006, Colombia

  • Novartis Investigative Site

    WITHDRAWN

    Guatemala City, GTM, 01010, Guatemala

  • Novartis Investigative Site

    RECRUITING

    Guatemala City, 01015, Guatemala

  • Novartis Investigative Site

    RECRUITING

    Debrecen, Hajdu Bihar Megye, 4032, Hungary

  • Novartis Investigative Site

    RECRUITING

    Budapest, 1033, Hungary

  • Novartis Investigative Site

    RECRUITING

    Budapest, H-1083, Hungary

  • Novartis Investigative Site

    RECRUITING

    Eger, 3300, Hungary

  • Novartis Investigative Site

    WITHDRAWN

    Kaposvár, 7400, Hungary

  • Novartis Investigative Site

    WITHDRAWN

    Nagykanizsa, 8800, Hungary

  • Novartis Investigative Site

    RECRUITING

    Szigetvár, 7900, Hungary

  • Novartis Investigative Site

    RECRUITING

    Tarnów, Poland, 33-100, Poland

  • Novartis Investigative Site

    RECRUITING

    Lodz, Łódź Voivodeship, 90-329, Poland

  • Novartis Investigative Site

    RECRUITING

    George, Western Cape, 6529, South Africa

  • Novartis Investigative Site

    RECRUITING

    Cape Town, 7531, South Africa

  • Novartis Investigative Site

    RECRUITING

    Esplugues, Barcelona, 08950, Spain

  • Novartis Investigative Site

    RECRUITING

    Sabadell, Barcelona, 08208, Spain

  • Novartis Investigative Site

    WITHDRAWN

    Mérida, Extremadura, 06800, Spain

  • Novartis Investigative Site

    RECRUITING

    Barcelona, 08035, Spain

  • Novartis Investigative Site

    RECRUITING

    London, SE5 9RS, United Kingdom

  • Novartis Investigative Site

    RECRUITING

    Stoke-on-Trent, ST4 6QG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.